Compare United States Brent Oil Fund LP (BNO) vs Crispr Therapeutics AG (CRSP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
United States Brent Oil Fund LP vs Crispr Therapeutics AG — how do they compare? United States Brent Oil Fund LP trades at $50.42, while Crispr Therapeutics AG trades at $53.94 (market cap $5.23B). The key difference: United States Brent Oil Fund LP is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| BNO | CRSP | |
|---|---|---|
Sector | Commodities - Energy | Health |
52-Week High | $60.13 | $76.78 |
52-Week Low | $27.20 | $44.34 |
Market Cap | — | $5.23B |
Enterprise Value | — | $3.65B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNO shows bullish momentum with a 1.22% gain to $50.72, supported by strong technical indicators including bullish moving averages. The oil market faces supply constraints from Middle East tensions and OPEC demand forecast cuts, creating volatility. Recent news highlights ongoing Strait of Hormuz disruptions affecting global oil flows, with the International Energy Agency warning of depleting stockpiles.
The outlook remains volatile with supply risks supporting prices, but demand destruction and inventory builds pose headwinds. Key resistance at $52 and support at $50 will determine near-term direction. Oil market fundamentals suggest continued price pressure from geopolitical factors, though weakening demand forecasts could limit upside potential.
CRISPR Therapeutics (CRSP) trades at $54.02, up 0.95% on the day, with strong technical momentum and bullish moving average signals. The company reported a Q2 2026 loss of $0.94 per share, beating estimates, while revenue growth is driven by CASGEVY sales expansion. Analyst sentiment remains positive with a $82.67 consensus price target representing 53% upside potential.
Despite promising pipeline developments and strong analyst support, CRSP faces significant fundamental challenges including negative profit margins, substantial cash burn, and high valuation multiples. The stock's near-term performance will depend on successful clinical trial outcomes and commercial execution of its gene-editing therapies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About United States Brent Oil Fund LP
BNO is a commodity ETF that tracks the daily price of Brent crude oil futures. It provides exposure to the international oil benchmark, which often trades at a premium to the U.S. WTI benchmark, and is primarily used for short-term trading due to roll costs.
Read more on BNO →About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →
